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Abstract 
Background: Obesity is known to promote mild hyperthyrotropinaemia by unknown metabolic mechanisms. This 
investigation aimed to explore the association between thyroid function and metabolic phenotype in euthyroid 
obese individuals. Retrospective, cross-sectional study. Tertiary care center.
Methods: 952 euthyroid obese individuals referred to our Institution for obesity. Serum levels of TSH, FT4, glucose, 
insulin and HbA1c levels, lipid profile, liver function and proinflammatory indices were measured. Resting energy 
expenditure was assessed by indirect calorimetry and body composition by bioimpedance analysis.
Results: On admission, 306 patients had previously diagnosed diabetes mellitus on treatment with metformin, while 
113 patients were diagnosed with incident diabetes mellitus. Serum TSH levels were similar between metformin-
treated diabetic subjects and metformin-untreated subjects, while FT4 was slightly but significantly higher in the 
former. Analysis stratified by TSH categories found no effect of metformin-treated diabetes mellitus on TSH levels. 
Interestingly, obese patients with incident diabetes showed lower TSH levels than normoglycaemic ones. In correla-
tion studies on the whole dataset, an association related TSH to BMI and total cholesterol levels, which was lost upon 
adjustment for individual confounders. FT4 levels were found to be inversely related to BMI, insulin resistance and 
triglycerides, while being directly associated with HDL-cholesterol levels. These correlations remained unaltered after 
controlling for individual confounders. In multivariate linear regression analysis, TSH was associated with FT4, total 
cholesterol and BMI values. Significant predictors of FT4 were constituted by previously diagnosed diabetes mellitus, 
BMI, TSH and age.
Conclusions: In euthyroid obese subjects, FT4 seems more closely related than TSH levels to parameters of cardio-
metabolic risk. TSH levels did not differ between metformin-treated and untreated subjects, while they were lower in 
patients with incident diabetes mellitus compared to normoglycaemic ones.
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Background
Thyroid disorders impact body weight in multiple ways, 
and hypothyroidism is traditionally claimed as a con-
tributor of weight accrual via altered metabolic efficiency, 
water retention, decreased lipolysis [1]. Nonethe-
less, case-control studies and epidemiological surveys 
revealed that TSH levels tend to follow body weight 
accrual as well as development of obesity and insulin 
resistance, independent of hypothyroidism [2–9]. The 
causal mechanism underlying this link remains uni-
dentified, yet a compensatory response operated by the 
hypotalamo-pituitary unit via leptin and directed to 
counteract weight accrual, is very likely involved [1, 10].
Obesity, type 2 diabetes mellitus (T2DM) and thyroid 
diseases are the most frequent endocrine disorders and 
often coexist in the same individual [11]. Following an 
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studies have shown that the antidiabetic drug metformin 
can decrease TSH levels in patients with subclinical and/
or overt hypothyroidism, while other antidiabetic agents 
do not yield such effect [13–17]. In subsequent studies, 
it has been clarified that metformin can alter TSH levels 
also in euthyroid subjects if TSH levels lay in the mid-
high normal range (i.e., >2.5–3.0 mIU/L) [18–20].
Considering the metabolic derangement commonly 
associated with obesity as well as the frequent use of 
metformin in overweight patients owing to its insulin-
sensitizing effect and potential reduction of body weight 
[21], we aimed at assessing the impact of the metabolic 
phenotype, metformin-treated diabetes mellitus, and 
incident diabetes mellitus on thyroid function in euthy-
roid obese patients, and thus further investigating the 
potential thyroidal determinants of cardiometabolic risk 
in this setting.
Methods
This study enrolled 952 obese patients [M/F = 410/542, 
median age 58 (IQR 52–66) years, median BMI 45 (IQR 
41.4–49.4) kg/m2] referred to our institution for work-up 
and rehabilitation of obesity and its comorbidities. Sub-
jects included in the current study were participants of 
the TONDO study (T2DM of new diagnosis in obesity), 
an ongoing study initiated in 2012 and designed to inves-
tigate the relationship between glucose abnormalities and 
indices of organ damage in subjects with uncomplicated 
and complicated obesity [22], and were included accord-
ing to inclusion criteria and availability of complete thy-
roid function assessment. Written consent was obtained 
from all patient, after full explanation of the purpose 
and nature of the study. The investigation was approved 
by the local ethical committee, functioning according to 
the 3rd edition of the Guidelines on the Practice of Ethi-
cal Committees in Medical Research. The current cohort 
included: (1) 646 euthyroid obese subjects [group OB-Eu; 
males/females  =  283/363, median age 55 (IQR 48–65) 
years, BMI 43.7 (IQR 40–48.9) kg/m2], 113 of whom were 
diagnosed on admission with T2DM based on fasting 
glycaemia and/or HbA1c levels; (2) 306 euthyroid obese 
subjects with T2DM on treatment with metformin for at 
least 6 months [group OB-EuM; males/females, 127/179; 
median age 58 (IQR 50–65) years; BMI 45.6 (IQR 41.4–
49.6)  kg/m2; median diabetes duration 8.1  years (IQR 
6.9–9.4)]. Exclusion criteria were age below 18 or above 
90 years; previous or current use of medications poten-
tially interfering with thyroid function (such as amiodar-
one, steroids or lithium carbonate therapy); previous or 
current treatment with levo-thyroxine; known autoim-
mune diseases (including thyroid) and/or hypothyroid-
ism; type 1 diabetes mellitus; pregnancy; liver or kidney 
disease. In case of TSH value  >4.5  mIU/L, a condition 
not mandatorily indicative of thyroid dysfunction in obe-
sity, patients underwent a preliminary thyroid screening 
inclusive of re-analysis of TSH and measurement of fT3, 
fT4 and anti-thyroid antibody titer, to exclude true thy-
roid hypofunction. Screening test included glucose and 
insulin levels, lipid profile, indices of liver function and 
proinflammatory state, in fasting conditions. Patients 
were not prescribed diet therapy, dietary supplements, 
or antiobesity compounds for at least 3 months prior to 
entering the study.
Body measurements
All subjects underwent body measurements wearing light 
underwear, in fasting conditions after voiding. Weight 
and height were measured to the nearest 0.1  kg and 
0.1  cm, respectively. BMI was expressed as body mass 
(kg)/height (m)2. Obesity was defined for any BMI over 
30 kg/m2 [23]. Waist circumference was measured mid-
way between the lowest rib and the top of the iliac crest 
after gentle expiration; hip was measured as the greatest 
circumference around the nates. Anthropometric data 
were expressed as the mean of two measurements.
Fat mass and free fat mass, expressed as percentage of 
total body mass, were assessed by bio-impedance analy-
sis (BIA, 101/S Akern; Florence, Italy) the morning after 
overnight fasting and after voiding. The two vector com-
ponents of impedance (i.e. resistance and reactance) 
were obtained by single measurements; before each test-
ing session, the external calibration of the instrument 
was checked with a calibration circuit of known imped-
ance value. The mean coefficient of variation was 1 % for 
within-day and 3  % for weekly intraindividual measure-
ments in the steady-state condition in either site and 2 % 
for interoperator variability.
Resting energy expenditure (REE) was expressed in 
kilocalories per 24  h and determined in a thermoregu-
lated room (22–24 °C) by computed open-circuit indirect 
calorimetry, measuring resting oxygen uptake and resting 
carbon dioxide production by a ventilated canopy (Sen-
sormedics, Milan, Italy) at 1-min intervals for 30 min and 
expressed as 24 h value. Predicted REE was calculated by 
the Harris–Benedict formula and allowed to test for met-
abolic efficiency.
Laboratory tests
Insulin resistance was calculated by the homeostatic 
model of insulin resistance (HOMA-IR) index: insulin 
(mIU/L) ×  [glucose (mmol/L)/22.5]. A HOMA-IR value 
greater than 2.0 was considered indicative of insulin 
resistance, as obtained in a sample of the Italian popu-
lation [24]. The homeostatic model of β cell function 
(HOMA-B) was used to describe the functionality of 
pancreatic beta cells and calculated using the following 
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formula: 20 [insulin (mIU/L)/glucose (mmol/L)  −  3.5]. 
HbA1c levels were determined in 290 patients of the 
metformin-untreated group and all metformin-treated 
patients. ADA recommendations for 2012 [25] were used 
for the definition of glucose metabolism and T2DM based 
on fasting plasma glucose (FPG) and glycated hemo-
globin (HbA1c), as follows: normal FPG if <5.6 mmol/L; 
impaired FPG (IFG) if FPG was 5.5–6.9 mmol/L; T2DM 
if FPG was  ≥7.0  mmol/L on 2  days apart. HbA1c val-
ues of 5.7 and 6.5  % were considered as the threshold 
of normal glucose metabolism and T2DM, respectively. 
Undiluted serum samples were assayed for fT4 and TSH 
using an automated chemiluminescence assay system 
(Immulite 2000; DPC, Los Angeles, CA). The principle of 
the method is a two-site, solid-phase chemiluminescent 
immunometric assay or competitive immunoassay. Nor-
mal values for TSH are 0.4–4.5 mIU/L, and for fT4 102.9-
244.5 nmol/L. Insulin levels were measured by immulite. 
Glucose, total cholesterol, high-density (HDL) and low-
density lipoprotein (LDL) cholesterol, and triglycerides 
were measured by enzymatic methods (Roche Diagnos-
tics, Mannheim, Germany). Fibrinogen levels were deter-
mined with the Clauss methodology by Hemosil assay 
(IL Coagulation System, Instrumentation Laboratory, 
Bedford, MA). Ultrasensitive C-reactive protein (CRP) 
was measured by CRP (latex) HS Roche kit, having sen-
sitivity of 0.03 nmol/L, intraassay and interassay CVs of 
2.51–5.35 and 4.25–5.79  %, respectively, as reported by 
the manufacturer. Alkaline phosphatase, aspartate ami-
notransferase (AST) and alanine aminotransferase (ALT) 
were assayed according to the International Federation 
of Clinical Chemistry (IFCC), without pyridoxal-5′-
phosphate, using the Cobas Integra 800 (Roche Diag-
nostics). Gamma-glutamyltranspeptidase (GGT) was 
measured by enzymatic colorimetric test using Roche/
Hitachi 904/911/912/917/modular (Roche Diagnostics).
Statistics
Statistical analysis was performed using SPSS version 18 
(Somers, NY, USA) on log transformed data to correct for 
the non-Gaussian distribution obtained by the Shapiro–
Wilk test. Values are expressed as medians and interquar-
tile ranges. Mann–Whitney test was used for comparison 
between subgroups. Spearman’s correlation analysis and 
the Chi square were used to identify significant asso-
ciations between variables of interest. The role of non-
collinear variables on TSH and fT4 levels was tested by 
stepwise multiple regression analysis using as independ-
ent variables age, gender, BMI, use of metformin, total 
cholesterol and fT4 or TSH, depending on whether TSH 
or fT4 levels were analyzed, respectively. HOMA-IR and 
waist circumference were employed as additional covari-
ates in this model after exclusion of potential collinear 
variables. Logistic regression analysis to test the effect of 
metformin-treated diabetes mellitus and other variables 
of interest on the levels of thyroid parameters. Statistical 
significance was set at 5 %.
Results
A summary of anthropometric and biochemical data 
are reported in Table  1. BMI values were comprised 
between 30–73.6  kg/m2, and were  >40  kg/m2in 78.8  % 
(750 patients), >35–39.9 kg/m2 in 17.8 % (172 patients), 
and >30–34.9 kg/m2 in 3.1 % of cases (30 patients). The 
metformin-treated diabetic subgroup exhibited greater 
BMI, waist circumference and fat mass than their coun-
terpart. Both subpopulations were, however, severely 
insulin resistant and HOMA-IR exceed the normal 
threshold of 2 [23] in 81.6  % of metformin-untreated 
and 87 % of metformin-treated diabetic patients. Ninety-
four metformin-treated diabetic subjects were on statins 
at the time of the study, which likely explained the dif-
ferences in total and LDL-cholesterol noted between 
groups.
Analysis of thyroid function showed a mild increase 
in TSH levels in a subset of 30 patients (5.6 %). None of 
these harbored any increase in anti-thyroid antibody titer 
or abnormal free thyroid hormone levels. Table  1 illus-
trates similar TSH levels between metformin-treated dia-
betic patients and metformin-untreated subjects. Based 
on the TSH reducing effects previously found to be elic-
ited by metformin, our attention was mainly focused on 
TSH values in metformin users and non-users, yet data 
dichotomization by median TSH levels o 1.72  mIU/L 
showed a comparable distribution of metformin users 
between top and bottom TSH bearers (24.3 and 23.2 %, 
respectively), with results being equivalent if TSH was 
stratified by quartiles (Fig. 1) or logistic regression anal-
ysis (Table  2). Oppositely, analysis of fT4 levels showed 
significantly higher fT4 levels in metformin-treated dia-
betic subjects compared to metformin-untreated ones. 
Interestingly, when a subset of 113 metformin-untreated 
obese patients with incident diabetes mellitus was con-
sidered separately, these patients exhibited lower TSH 
[1.50 (IQR 1.12–2.01) vs. 1.80 (IQR 1.24–2.51)  mIU/L; 
p = 0.02] and greater abdominal obesity [waist, 132 (IQR 
121–141) vs. 114.7 (IQR 100.4–132.5) cm; p  <  0.001] 
than the normoglycaemic counterpart, devoid of differ-
ences in fT4 levels [11.1 (IQR 10.2–12.4) vs. 11.3 (IQR 
10.2–12.6) pg/mL] or BMI values [44.5 (IQR 40.3–49.3) 
vs. 43.5 (IQR 39.5–48.2) kg/m2]. Gender stratification 
showed no differences in TSH and fT4 levels (data not 
shown).
Bivariate regression analyses on the whole dataset 
depicted a significant negative correlation between TSH 
and fT4 levels (rho = −0.091, p = 0.005), with each being 
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weakly correlated in opposite direction with BMI (TSH: 
rho = 0.078, p = 0.02; fT4: rho = −0.074, p = 0.02) and 
waist circumference (TSH: rho  =  0.063, p  =  0.06; fT4: 
rho = −0.066, p = 0.04). The relationship between TSH 
and fT4 persisted after controlling for age, BMI, gen-
der, HOMA-IR and the use of metformin (r  =  0.088, 
p =  0.008). No correlation was observed between TSH 
and age. In sub-group analysis, patients aged  >70  year 
(103 cases, 10.8  %) showed comparable TSH levels 
with the remainders (1.68  mUI/L [IQR 1.25–2.46] vs 
1.72 mUI/mL, [IQR 1.21–2.47]); the possibility that this 
represented a ‘survivor’ sample of patients was hinted by 
the finding of a slightly healthier metabolic profile when 
compared to the younger counterpart, i.e. lower levels of 
total and LDL cholesterol, triglycerides, and HbA1c (data 
not shown). When thyroid function was plotted against 
serum parameters of cardiovascular risk in the popu-
lation as a whole, TSH was only associated with total 
cholesterol (rho =  0.080, p =  0.01). Of note, fT4 levels 
were inversely related to triglycerides (rho  =  −0.091, 
p = 0.005), insulin (rho = −0.079, p = 0.02) and HOMA-
IR (rho = −0.083, p = 0.01), and directly to HDL-choles-
terol (rho = 0.106, p = 0.001). In testing the relationship 
between thyroid function and cardio-metabolic vari-
ables after controlling for potential confounders (i.e. 
age, gender, BMI, incident diabetes mellitus, use of met-
formin, use of statins, smoking), only fT4 remained cor-
related with age, BMI and HDL-cholesterol, while the 
Table 1 Summary of  anthropometric and  biochemical data obtained in  the whole study population, in  the euthyroid 
metformin-treated obese diabetic subpopulation (OB-EuM) and  the euthyroid obese metformin-untreated subpopula-
tion (Ob-Eu)
HbA1c levels in Ob-Eu refer to measurement in a subgroup of 290 patients. Data are expressed as medians (with interquartile range in parentheses). Comparison 
between populations was performed by Mann–Whitney test on log-transformed data and χ2 test
BMI body mass index; REE resting energy expenditure; HOMA-IR homeostatic model of insulin resistance; HOMA-B homeostatic model of β cell function; LDL low 
density lipoprotein; HDL high density lipoprotein; AST aspartate aminotransferase; ALT alanine aminotransferase; γGT gamma glutamiltransferase; ALP alkaline 
phosphatase; CRP C-reactive protein
Variables Whole population (n = 952) OB-EuM (n = 306) Ob-Eu (n = 646) p
Males/females 410/542 127/179 283/363 0.5
Age (years) 56 (49–65) 58 (50–65) 55 (48–65) 0.07
BMI (kg/m2) 44.4 (40.5–48.9) 45.6 (41.4–49.6) 43.7 (40.0–48.7) 0.003
Weight (kg) 117.8 (102.8–133.5) 118.3 (106.0–134.0) 117.3 (101.6–133.1) 0.09
Height (cm) 161.8 (155–171) 161 (155–170) 162 (155–171) 0.3
Waist (cm) 129 (119–138) 131 (122–140) 127 (116–137) <0.001
Waist-to-hip ratio 0.96 (0.89–1.92) 0.97 (0.91–1.04) 0.94 (0.88–1.02) <0.001
REE (kcal/day) 1909 (1651–2247) 1963 (1740–2280) 1884 (1598–2233) 0.003
Fat mass (%) 46.3 (41.0–51.8) 47.3 (41.9–52.6) 45.7 (40.4–51.3) 0.009
Body water (%) 39.7 (36.2–44.2) 39.5 (36.3–43.9) 39.8 (36.2–44.4) 0.7
TSH (mIU/L) 1.72 (1.21–2.47) 1.72 (1.19–2.45) 1.72 (1.22–2.47) 0.7
fT4 (nmol/L) 146.3 (132.5–162.1) 151.9 (135.1–163.5) 145.4 (131.3–162.2) <0.001
Insulin (pmol/L) 100.7 (65.9–145.8) 98.6 (62.5–150.0) 102.1 (68.1–143.1) 0.5
Glucose (mmol/L) 5.77 (5.05–7.21) 7.38 (6.05–8.99) 5.38 (5.38–6.22) <0.001
HbA1c (%) 6.6 (6.0–7.9) 7.5 (6.5–8.7) 6.1 (5.7–6.7) <0.001
HOMA-IR 4.0 (2.5–6.1) 4.7 (2.9–7.2) 3.7 (2.3–5.6) <0.001
HOMA-B 125.2 (72.1–214.1) 76.3 (42.6–133.1) 152.0 (97.1–248.3) <0.001
Cholesterol (mmol/L) 5.10 (4.38–5.80) 4.79 (4.01–5.44) 5.26 (4.66–5.98) <0.001
LDL (mmol/L) 3.12 (2.49–3.76) 2.75 (2.16–3.39) 3.30 (2.70–3.93) <0.001
HDL (mmol/L) 1.09 (0.91–1.35) 1.04 (0.85–1.27) 1.11 (0.93–1.37) <0.001
Triglycerides (mmol/L) 1.59 (1.23–2.18) 1.73 (1.31–2.37) 1.55 (1.20–2.09) <0.001
AST (μkat/L) 0.35 (0.28–0.48) 0.35 (0.28–0.50) 0.35 (0.30–0.48) 0.8
ALT (μkat/L) 0.45 (0.32–0.70) 0.43 (0.32–0.70) 0.45 (0.32–0.70) 0.8
γGT (μkat/L) 0.48 (0.32–0.75) 0.50 (0.33–0.87) 0.47 (0.30–0.72) 0.07
ALP (μkat/L) 1.64 (1.14–3.02) 1.25 (1.04–1.65) 2.27 (1.25–3.35) <0.001
CRP (nmol/L) 5.71 (2.86–10.48) 5.71 (2.86–11.43) 5.71 (3.81–10.48) 0.5
Fibrinogen (μmol/L) 11.64 (10.17–13.38) 11.44 (9.91–13.17) 11.76 (10.29–13.52) 0.04
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correlation with triglycerides approached statistical sig-
nificance (Table  3). No relationship was seen between 
thyroid function and C-reactive protein, fibrinogen and 
liver function tests, but with alkaline phosphatase (TSH: 
rho  =  −0.098, p  =  0.002; fT4: rho =  0.070, p  =  0.03). 
Likewise, no association related thyroid function to REE 
and metabolic efficiency, as well as BIA-derived param-
eters of body composition (data not shown).
In multivariate linear regression analysis, TSH was best 
predicted by fT4 (standardized β = −0.079, p = 0.015), 
total cholesterol (standardized β = 0.074, p = 0.02) and 
BMI (standardized β  =  0.065, p  =  0.04). Replacement 
of BMI with waist circumference did not reach statisti-
cal significance. When FT4 levels were tested as the 
dependent variable, they were predicted by TSH (stand-
ardized β = −0.84, p = 0.01), metformin-treated diabe-
tes mellitus (standardized β  =  0.087, p  =  0.008), BMI 
(standardized β = −0.83, p = 0.012) and age (standard-
ized β = −0.80, p =  0.015). When waist circumference 
replaced BMI, it also entered the regression equation 
(standardized β = −0.077, p = 0.021). HOMA-IR did not 
enter the regression equation both when TSH and fT4 
levels were tested.
Discussion
Obesity is conventionally regarded as the result of unbal-
anced calorie intake and impaired energy expenditure 
acting on a predisposed genetic setting. A common 
explanatory model encompasses the lipostatic regulation 
system, in which energy stores generate signals that are 
compared with targets encoded in the brain, and differ-
ences between these drive our food intake levels, activ-
ity patterns, and resting and active metabolisms [26]. 
Although obesity predisposes to hyperthyrotropinaemia 
and reductions in fT4 levels [1, 2], TSH levels can still 
provide a peripheral index of thyroid activity also in the 
obese state [27]. So far, analyses on the metabolic cor-
relates of thyroid function in obesity have provided lit-
tle evidence, or were conducted in small cohorts so as 
to draw definitive conclusions [1, 2]. In this regard, a 
potential confounder is constituted by the antidiabetic 
Fig. 1 Comparison of TSH quartiles between obese euthyroid obese 
patients with diabetes and treated with metformin (Met) and those 
without diabetes and not treated with metformin (No Met). Medians 
(diamonds) and interquartile ranges (lines) are displayed
Table 2 Logistic regression analysis on  values of  TSH 
and BMI dichotomized by median values (0 = bottom val-
ues; 1 = top values) in the population as a whole
Odds ratio and 95 % confidence intervals are displayed. BMI body mass index; 
REE resting energy expenditure; HOMA-IR homeostatic model of insulin 
resistance. Use of metformin was categorized as 0 = no use of metformin, 
1 = use of metformin. Significant values are in italics
Variables TSH BMI
Age 0.98 (0.96–0.99) 0.99 (0.98–1.01)
Female gender 1.08 (0.59–1.73) 5.67 (3.61–8.90)
TSH – 1.05 (0.89–1.24)
BMI 0.97 (0.94–1.01) –
REE 1.00 (0.99–1.00) 1.003 (1.002–1.003)
HOMA-IR 1.01 (0.99–1.02) 0.99 (0.98–1.01)
Use of metformin 1.09 (0.78–1.52) 1.29 (0.90–1.85)
Table 3 Correlation analysis between  thyroid function 
and  phenotypic variables of  interest in  the obese group 
as a whole, after controlling for age, gender, BMI and use 
of metformin
Italic values indicate p-values
Underlined values indicate significance
Italic underlined values indicate statistically significant p-values
Age and BMI were omitted as covariates when measured as independent 
variables
Variables TSH fT4
r p r p
Age −0.05 0.1 −0.08 0.01
BMI 0.05 0.09 −0.09 0.006
Waist 0.04 0.3 0.02 0.5
Percent fat mass 0.09 0.02 0.07 0.06
Cholesterol 0.506 0.09 −0.02 0.5
HDL 0.03 0.3 0.13 0.001
LDL 0.04 0.3 −0.05 0.1
Triglycerides 0.05 0.2 −0.07 0.06
Insulin 0.01 0.7 −0.03 0.3
HOMA-IR 0.01 0.8 −0.04 0.2
HOMA-B 0.02 0.5 0.01 0.7
AST 0.03 0.4 −0.07 0.06
ALT −0.003 0.9 −0.003 0.9
γGT 0.004 0.2 −0.03 0.4
Alkaline phosphatase −0.13 0.001 0.09 0.02
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agent metformin, based on its ability to reduce TSH lev-
els in subjects with hypothyroidism and in those with 
euthyroidism harboring normal-high TSH levels [11–15, 
18–20]. Metformin acts as insulin-sensitizer in multiple 
ways, such as by decreasing hepatic glucose production 
through inhibition of the mitochondrial respiratory-
chain complex 1, by activating the cellular metabolic 
sensor AMPK, by increasing glucagon-like peptide 1 
(GLP-1) levels, as well as by inducing islet incretin recep-
tor gene expression [28–31]. The exact mechanisms 
linking metformin effects to variations in pituitary TSH 
secretion are currently unknown, but possibly involve 
inhibition of hypothalamic AMPK, counteraction of cen-
tral T3 effects, dopaminergic effects and/or inhibition 
of pituitary TSH secretion [11, 32, 33]. In the current 
study, first of all we documented comparable TSH levels 
between obese patients treated and not treated with met-
formin. This result was confirmed by multiple statistical 
approaches. Oppositely, a slight yet significant increase in 
fT4 levels was seen in metformin-treated subjects com-
pared with their untreated counterpart. This latter find-
ing contrasts with the observation that metformin leaves 
unaltered free thyroid hormone levels [34], and possibly 
reflects an effect played by obesity on thyroid hormone 
metabolism either mediated by type 2 deiodinase activ-
ity, TH binding to TBG, or thyroxine degradation. How-
ever, we do not exclude that such finding simply results 
from metabolic differences existing between subgroups, 
since metformin-treated subjects were slightly older 
and mildly more insulin resistant, showed a more cen-
tral distribution of body fat and higher BMI compared 
to the metformin-untreated counterpart. Along this line 
of reasoning, the positive correlation between fat mass 
and fT4 found by others [35] supports the hypothesis 
that abdominal adiposity may increase free thyroid hor-
mone. In addition, diabetes mellitus can increase per se 
fT3 inactivation to rT3 and decrease T4 conversion to T3 
due to lower type 2 deiodinase activity [36], while meta-
bolic syndrome can lead to higher fT4 levels in obese 
subjects [37]. Our obese patients with incident diabetes 
mellitus were found to harbor lower TSH compared with 
their metformin-untreated counterpart. In this subgroup, 
individual analysis found no potential case of subclini-
cal dysfunction and no significant metabolic impact was 
documented in correlation analyses likely due to the sam-
ple dimension and the overall high rate of severe obesity 
in our study (nearly 80 %). Further investigations in larger 
datasets are warranted to verify the clinical significance 
of this observation.
Together, our results pinpoint potentially different 
metabolic roles for TSH and fT4 in the obese setting. In 
general, TSH was associated with increasing BMI and 
total but not HDL cholesterol levels. These associations 
disappeared after controlling for individuals’ confound-
ers. Oppositely, fT4 levels showed an inverse relation 
with BMI, insulin, HOMA-IR, triglycerides, in conjunc-
tion with a direct association with HDL-cholesterol. fT4 
associations with the metabolic phenotype remained sig-
nificant after adjustment for potential confounders. This 
leads us to speculate that fT4 reflects better than TSH the 
cardiometabolic risk of obesity: according to this view, 
TSH levels mirror the obese phenotype, while fT4 levels 
act as a proxy of the metabolic status related to the obese 
phenotype. Previous studies in morbidly obese patients 
found an association of increasing TSH, and less signifi-
cantly decreasing FT4, with insulin and insulin resistance 
[3, 38, 39], yet none was controlled for individual con-
founders. On the other hand, population studies related 
low fT4 more tightly to cardiometabolic indices (BMI, 
insulin resistance, lipid profile and intima media thick-
ness) than high TSH levels [40–43]. In a Korean study on 
6241 non diabetic euthyroid subjects, those with the low-
est fT4 quartile had twice the risk for insulin resistance 
as compared to those in the highest quartile after adjust-
ment for age, sex, metabolic, and life style factors [44]. 
Nevertheless, the NHANES 2007–2008 analysis on 3114 
euthyroid healthy men and women found that only TSH 
levels, and to a lesser degree fT3, were correlated with 
BMI and waist circumference, while fT4 levels were not 
[8]. Likewise, the Asklepios Study on 2315 healthy euthy-
roid middle-aged men and women found that a higher 
fT3–fT4 ratio (index of conversion from fT4 to fT3) was 
predictive of an unfavorable metabolic profile [45]. Dif-
ferences in prevalence and degree of obesity, fat partition, 
genetic background, and insulin sensitivity may contrib-
ute to explain the observed discrepancies.
In conclusion, fT4 levels appeared to be related to the 
overall metabolic phenotype of obese patients, while the 
metabolic impact of TSH was less prominent. Incident 
diabetes seems associated with a reduction in TSH results, 
yet further studies in larger samples of euthyroid obese 
patients are needed to detail the individual clustering of 
TSH and fT4 levels with metabolic features in this setting.
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